Interaction of the endocrine system with inflammation: A function of energy and volume regulation

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Straub, Rainer H ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ENDOCRINE SYSTEM; ENERGY METABOLISM; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ENDOCRINE SYSTEM; ENERGY METABOLISM; HUMANS; INFLAMMATION;

EID: 84893869859     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4484     Document Type: Review

References (149)

1. Besedovsky HO, Del Rey A. Immune-neuro-endocrine interactions. Endocr Rev 1996, 17:64-102.
2. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999, 79:1-71.
3. Sternberg EM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 2006, 6:318-328.
4. Straub RH, Cutolo M, Buttgereit F, Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010, 267:543-560.
5. Spies CM, Straub RH, Buttgereit F. Energy metabolism and rheumatic diseases: from cell to organism. Arthritis Res Ther 2012, 14:216-225.
6. Straub RH. Evolutionary medicine and chronic inflammatory state - known and new concepts in pathophysiology. J Mol Med 2012, 90:523-534.
7. Straub RH, Besedovsky HO. Integrated evolutionary, immunological, and neuroendocrine framework for the pathogenesis of chronic disabling inflammatory diseases. FASEB J 2003, 17:2176-2183.
8. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure. Neuroendocrinology 1997, 66:54-62.
9. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999, 19:1986-1991.
10. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 1999, 19:972-978.
11. Yamauchi T, Sato H. Nutritional status, activity pattern, and dietary intake among the Baka hunter-gatherers in the village camps in cameroon. Afr Study Mongr 2000, 21:67-82.
12. Taubes G. Treat obesity as physiology, not physics. Nature 2012, 492:155.
13. Blumenthal S. From insulin and insulin-like activity to the insulin superfamily of growth-promoting peptides: a 20th-century odyssey. Perspect Biol Med 2010, 53:491-508.
14. Calder PC, Dimitriadis G, Newsholme P. Glucose metabolism in lymphoid and inflammatory cells and tissues. Curr Opin Clin Nutr Metab Care 2007, 10:531-540.
15. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004, 14:395-403.
16. Michal G. Biochemical Pathways 1999, Heidelberg Berlin: Spektrum Akademischer Verlag.
17. Blüher S, Kratzsch J, Kiess W. Insulin-like growth factor I, growth hormone and insulin in white adipose tissue. Best Pract Res Clin Endocrinol Metab 2005, 19:577-587.
18. Kawai M, Rosen CJ. The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am 2012, 41:323-333.
19. Kenyon AT, Knowlton K, Sandiford I. The anabolic effect of the androgens and somatic growth in man. Ann Intern Med 1944, 20:632-654.
20. Reifenstein EC, Albright F. The metabolic effect of steroid hormones in osteoporosis. J Clin Invest 1947, 26:24-56.
21. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The role of androgens and estrogens on healthy aging and longevity. J Gerontol A Biol Sci Med Sci 2012, 67:1140-1152.
22. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009, 30:23-32.
23. Imai Y, Youn MY, Inoue K, Takada I, Kouzmenko A, Kato S. Nuclear receptors in bone physiology and diseases. Physiol Rev 2013, 93:481-523.
24. Notelovitz M. Androgen effects on bone and muscle. Fertil Steril 2002, 77:S34-S41.
25. Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999, 276:E317-E325.
26. Barros RP, Gustafsson JA. Estrogen receptors and the metabolic network. Cell Metab 2011, 14:289-299.
27. Straub RH. The complex role of estrogens in inflammation. Endocr Rev 2007, 28:521-574.
28. Nicolaysen R. Studies upon the mode of action of vitamin D: the influence of vitamin D on the absorption of calcium and phosphorus in the rat. Biochem J 1937, 31:122-129.
29. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, Jurutka PW. Molecular mechanisms of vitamin D action. Calcif Tissue Int 2013, 92:77-98.
30. Girgis CM, Clifton-Bligh RJ, Hamrick MW, Holick MF, Gunton JE. The roles of vitamin D in skeletal muscle: form, function, and metabolism. Endocr Rev 2013, 34:33-83.
31. Neve A, Corrado A, Cantatore FP. Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol 2013, 228:1149-1153.
32. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol Metab 2008, 19:161-166.
33. Hwang YC, Jeong IK, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 2009, 25:768-772.
34. Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between obesity, metabolic risks and serum osteocalcin level in postmenopausal women. Gynecol Endocrinol 2012, 28:472-477.
35. Sullivan TR, Duque G, Keech AC, Herrmann M. An old friend in a new light: the role of osteocalcin in energy metabolism. Cardiovasc Ther 2013, 31:65-75.
36. Oury F, Sumara G, Sumara O, Ferron M, Chang H, Smith CE, Hermo L, Suarez S, Roth BL, Ducy P, Karsenty G. Endocrine regulation of male fertility by the skeleton. Cell 2011, 144:796-809.
37. Hozuki T, Imai T, Tsuda E, Matsumura A, Yamamoto D, Toyoshima T, Suzuki S, Yamauchi R, Hayashi T, Hisahara S, Shimohama S. Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study. Intern Med 2010, 49:371-376.
38. Szekely M. The vagus nerve in thermoregulation and energy metabolism. Auton Neurosci 2000, 85:26-38.
39. Thorens B, Larsen PJ. Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis. Curr Opin Clin Nutr Metab Care 2004, 7:471-478.
40. Mussa BM, Verberne AJ. The dorsal motor nucleus of the vagus and regulation of pancreatic secretory function. Exp Physiol 2013, 98:25-37.
41. Burcelin R, Dolci W, Thorens B. Portal glucose infusion in the mouse induces hypoglycemia: evidence that the hepatoportal glucose sensor stimulates glucose utilization. Diabetes 2000, 49:1635-1642.
42. Inoue S, Nagase H, Satoh S, Saito M, Egawa M, Tanaka K, Takamura Y. Role of the efferent and afferent vagus nerve in the development of ventromedial hypothalamic (VMH) obesity. Brain Res Bull 1991, 27:511-515.
43. Darmaun D, Matthews DE, Bier DM. Physiological hypercortisolemia increases proteolysis, glutamine, and alanine production. Am J Physiol 1988, 255:E366-E373.
44. Djurhuus CB, Gravholt CH, Nielsen S, Mengel A, Christiansen JS, Schmitz OE, Moller N. Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans. Am J Physiol Endocrinol Metab 2002, 283:E172-E177.
45. Gathercole LL, Morgan SA, Bujalska IJ, Hauton D, Stewart PM, Tomlinson JW. Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue. PLoS One 2011, 6:e26223.
46. Exton JH, Friedmann N, Wong EH, Brineaux JP, Corbin JD, Park CR. Interaction of glucocorticoids with glucagon and epinephrine in the control of gluconeogenesis and glycogenolysis in liver and of lipolysis in adipose tissue. J Biol Chem 1972, 247:3579-3588.
47. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 1982, 54:131-138.
48. Brodows RG, Pi S, Campbell RG. Sympathetic control of hepatic glycogenolysis during glucopenia in man. Metabolism 1975, 24:617-624.
49. Bartness TJ, Shrestha YB, Vaughan CH, Schwartz GJ, Song CK. Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol Cell Endocrinol 2010, 318:34-43.
50. Burniston JG, Ellison GM, Clark WA, Goldspink DF, Tan LB. Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others. Cardiovasc Toxicol 2005, 5:355-364.
51. Braun TP, Marks DL. Hypothalamic regulation of muscle metabolism. Curr Opin Clin Nutr Metab Care 2011, 14:237-242.
52. Kurose T, Seino Y, Nishi S, Tsuji K, Taminato T, Tsuda K, Imura H. Mechanism of sympathetic neural regulation of insulin, somatostatin, and glucagon secretion. Am J Physiol 1990, 258:E220-E227.
53. Lambert GW, Straznicky NE, Lambert EA, Dixon JB, Schlaich MP. Sympathetic nervous activation in obesity and the metabolic syndrome - causes, consequences and therapeutic implications. Pharmacol Ther 2010, 126:159-172.
54. Taborsky GJ, Mundinger TO. The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 2012, 153:1055-1062.
55. Gruol DJ, Campbell NF, Bourgeois S. Cyclic AMP-dependent protein kinase promotes glucocorticoid receptor function. J Biol Chem 1986, 261:4909-4914.
56. Nakada MT, Stadel JM, Poksay KS, Crooke ST. Glucocorticoid regulation of beta-adrenergic receptors in 3T3-L1 preadipocytes. Mol Pharmacol 1987, 31:377-384.
57. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007, 3:302-310.
58. Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M, Buchanan C. Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clin Endocrinol (Oxf) 1991, 35:47-54.
59. Frost RA, Fuhrer J, Steigbigel R, Mariuz P, Lang CH, Gelato MC. Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol (Oxf) 1996, 44:501-514.
60. Sarzi-Puttini P, Atzeni F, Scholmerich J, Cutolo M, Straub RH. Anti-TNF antibody therapy improves glucocorticoid- induced insulin-like growth factor-1 (IGF-1) resistance without influencing myoglobin and IGF-1 binding proteins 1 and 3. Ann Rheum Dis 2005, 65:301-305.
61. Corrick RM, Li L, Frank SJ, Messina JL. Hepatic growth hormone resistance after acute injury. Endocrinology 2013, 154:1577-1588.
62. Grunenwald S, Tack I, Chauveau D, Bennet A, Caron P. Impact of growth hormone hypersecretion on the adult human kidney. Ann Endocrinol (Paris) 2011, 72:485-495.
63. Fox CS, Pencina MJ, D'Agostino RB, Murabito JM, Seely EW, Pearce EN, Vasan RS. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med 2008, 168:587-592.
64. Potenza M, Via MA, Yanagisawa RT. Excess thyroid hormone and carbohydrate metabolism. Endocr Pract 2009, 15:254-262.
65. Liu YY, Brent GA. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends Endocrinol Metab 2010, 21:166-173.
66. Dimitriadis G, Maratou E, Alevizaki M, Boutati E, Psara K, Papasteriades C, Raptis SA. Thyroid hormone excess increases basal and insulin-stimulated recruitment of GLUT3 glucose transporters on cell surface. Horm Metab Res 2005, 37:15-20.
67. Silva JE, Bianco SD. Thyroid-adrenergic interactions: physiological and clinical implications. Thyroid 2008, 18:157-165.
68. Wojcicka A, Bassett JH, Williams GR. Mechanisms of action of thyroid hormones in the skeleton. Biochim Biophys Acta 2013, 1830:3979-3986.
69. Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol 2012, 23:22-26.
70. Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, varez-Guerra M, Garcia-Estan J. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 2006, 154:197-212.
71. Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci 2011, 32:734-739.
72. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-Gonzalez G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol (Oxf) 2009, 71:1-6.
73. Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr Opin Nephrol Hypertens 2004, 13:325-332.
74. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 1984, 64:170-259.
75. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008, 22:2465-2475.
76. Hatton R, Stimpel M, Chambers TJ. Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 1997, 152:5-10.
77. Lynn H, Kwok T, Wong SY, Woo J, Leung PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 2006, 38:584-588.
78. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006, 24:581-589.
79. Rammos G, Tseke P, Ziakka S. Vitamin D, the renin-angiotensin system, and insulin resistance. Int Urol Nephrol 2008, 40:419-426.
80. Garcia-Leme J, Fortes ZB, Sannomiya P, Farsky SP. Insulin, glucocorticoids and the control of inflammatory responses. Agents Actions Suppl 1992, 36:99-118.
81. Hyun E, Ramachandran R, Hollenberg MD, Vergnolle N. Mechanisms behind the anti-inflammatory actions of insulin. Crit Rev Immunol 2011, 31:307-340.
82. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002, 45:924-930.
83. Heemskerk VH, Daemen MA, Buurman WA. Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev 1999, 10:5-14.
84. Clark R. The somatogenic hormones and insulin-like growth factor-1: stimulators of lymphopoiesis and immune function. Endocr Rev 1997, 18:157-179.
85. Svenson KL, Lundqvist G, Wide L, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism 1987, 36:940-943.
86. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006, 54:2765-2775.
87. El Magadmi M, Ahmad Y, Turkie W, Yates AP, Sheikh N, Bernstein RM, Durrington PN, Laing I, Bruce IN. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol 2006, 33:50-56.
88. Bennett AE, Silverman ED, Miller JJ, Hintz RL. Insulin-like growth factors I and II in children with systemic onset juvenile arthritis. J Rheumatol 1988, 15:655-658.
89. Johansson AG, Baylink DJ, af Ekenstam E, Lindh E, Mohan S, Ljunghall S. Circulating levels of insulin-like growth factor-I and -II, and IGF-binding protein-3 in inflammation and after parathyroid hormone infusion. Bone Miner 1994, 24:25-31.
90. Lemmey A, Maddison P, Breslin A, Cassar P, Hasso N, McCann R, Whellams E, Holly J. Association between insulin-like growth factor status and physical activity levels in rheumatoid arthritis. J Rheumatol 2001, 28:29-34.
91. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003, 27:S53-S55.
92. Gilliver SC. Sex steroids as inflammatory regulators. J Steroid Biochem Mol Biol 2010, 120:105-115.
93. Cutolo M, Sulli A, Straub RH. Estrogen metabolism and autoimmunity. Autoimmun Rev 2012, 11:A460-A464.
94. Masi AT, Josipovic DB, Jefferson WE. Low adrenal androgenic-anabolic steroids in women with rheumatoid arthritis (RA): gas-liquid chromatographic studies of RA patients and matched normal control women indicating decreased 11-deoxy-17-ketosteroid excretion. Semin Arthritis Rheum 1984, 14:1-23.
95. Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S. Sex hormone status of male patients with rheumatoid arthritis: evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation. Arthritis Rheum 1988, 31:1314-1317.
96. Straub RH, Vogl D, Gross V, Lang B, Schölmerich J, Andus T. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease. Am J Gastroenterol 1998, 93:2197-2202.
97. Cutolo M, Capellino S, Straub RH. Oestrogens in rheumatic diseases: friend or foe?. Rheumatology (Oxford) 2008, 47:iii2-iii5.
98. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013, 93:359-404.
99. Palin SL, McTernan PG, Anderson LA, Sturdee DW, Barnett AH, Kumar S. 17Beta-estradiol and anti-estrogen ICI:compound 182,780 regulate expression of lipoprotein lipase and hormone-sensitive lipase in isolated subcutaneous abdominal adipocytes. Metabolism 2003, 52:383-388.
100. Cutolo M, Plebani M, Shoenfeld Y, Adorini L, Tincani A. Vitamin D endocrine system and the immune response in rheumatic diseases. Vitam Horm 2011, 86:327-351.
101. Nikolic T, Roep BO. Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin D3-treated tolerogenic dendritic cells. Front Immunol 2013, 4:113.
102. Sambrook PN, Ansell BM, Foster S, Gumpel JM, Hesp R, Reeve J, Zanelli JM. Bone turnover in early rheumatoid arthritis. 1. Biochemical and kinetic indexes. Ann Rheum Dis 1985, 44:575-579.
103. Als OS, Riis BJ, Gotfredsen A, Christiansen C, Deftos LJ. Biochemical markers of bone turnover in rheumatoid arthritis. Relation to anti-inflammatory treatment, sex, and menopause. Acta Med Scand 1986, 219:209-213.
104. Magaro M, Altomonte L, Mirone L, Zoli A, Corvino G. Bone GLA protein (BGP) levels and bone turnover in rheumatoid arthritis. Br J Rheumatol 1989, 28:207-211.
105. Gevers G, Devos P, De RM, Dequeker J. Increased levels of osteocalcin (serum bone Gla-protein) in rheumatoid arthritis. Br J Rheumatol 1986, 25:260-262.
106. Pietschmann P, Machold KP, Wolosczuk W, Smolen JS. Serum osteocalcin concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1989, 48:654-657.
107. Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007, 117:289-296.
108. Sloan RP, McCreath H, Tracey KJ, Sidney S, Liu K, Seeman T. RR interval variability is inversely related to inflammatory markers: the CARDIA study. Mol Med 2007, 13:178-184.
109. Bruchfeld A, Goldstein RS, Chavan S, Patel NB, Rosas-Ballina M, Kohn N, Qureshi AR, Tracey KJ. Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. J Intern Med 2010, 268:94-101.
110. Dekkers JC, Geenen R, Godaert GL, Bijlsma JW, van Doornen LJ. Elevated sympathetic nervous system activity in patients with recently diagnosed rheumatoid arthritis with active disease. Clin Exp Rheumatol 2004, 22:63-70.
111. Buttgereit F, Burmester GR, Straub RH, Seibel MJ, Zhou H. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011, 63:1-9.
112. Gisslinger H, Svoboda T, Clodi M, Gilly B, Ludwig H, Havelec L, Luger A. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinology 1993, 57:489-495.
113. Jessop DS, Harbuz MS. A defect in cortisol production in rheumatoid arthritis: why are we still looking?. Rheumatology (Oxford) 2005, 44:1097-1100.
114. Straub RH, Herfarth H, Falk W, Andus T, Schölmerich J. Uncoupling of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis in inflammatory bowel disease?. J Neuroimmunol 2002, 126:116-125.
115. Härle P, Straub RH, Wiest R, Mayer A, Schölmerich J, Atzeni F, Carrabba M, Cutolo M, Sarzi-Puttini P. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. Ann Rheum Dis 2006, 65:51-56.
116. Pongratz G, Straub RH. Role of peripheral nerve fibres in acute and chronic inflammation in arthritis. Nat Rev Rheumatol 2013, 9:117-126.
117. Redelman D, Welniak LA, Taub D, Murphy WJ. Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network. Cell Immunol 2008, 252:111-121.
118. Andreassen M, Frystyk J, Faber J, Kristensen LO. GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist. Eur J Endocrinol 2012, 166:811-819.
119. Masternak MM, Bartke A. Growth hormone, inflammation and aging. Pathobiol Aging Age Relat Dis 2012, 2:17293.
120. Kelley KW, Weigent DA, Kooijman R. Protein hormones and immunity. Brain Behav Immun 2007, 21:384-392.
121. Denko CW, Malemud CJ. Role of the growth hormone/insulin-like growth factor-1 paracrine axis in rheumatic diseases. Semin Arthritis Rheum 2005, 35:24-34.
122. Saldanha C, Tougas G, Grace E. Evidence for anti-inflammatory effect of normal circulating plasma cortisol. Clin Exp Rheumatol 1986, 4:365-366.
123. Coari G, Di FM, Iagnocco A, Di Novi MR, Mauceri MT, Ciocci A. Intra-articular somatostatin 14 reduces synovial thickness in rheumatoid arthritis: an ultrasonographic study. Int J Clin Pharmacol Res 1995, 15:27-32.
124. Paran D, Elkayam O, Mayo A, Paran H, Amit M, Yaron M, Caspi D. A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis. Ann Rheum Dis 2001, 60:888-891.
125. Koseoglu F, Koseoglu T. Long acting somatostatin analogue for the treatment of refractory RA. Ann Rheum Dis 2002, 61:573-574.
126. Imhof AK, Gluck L, Gajda M, Lupp A, Brauer R, Schaible HG, Schulz S. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum 2011, 63:2352-2362.
127. Pozzo AM, Kemp SF. Growth and growth hormone treatment in children with chronic diseases. Endocrinol Metab Clin North Am 2012, 41:747-759.
128. De VP, Incerpi S, Pedersen JZ, Luly P, Davis FB, Davis PJ. Thyroid hormones as modulators of immune activities at the cellular level. Thyroid 2011, 21:879-890.
129. Nishizawa Y, Fushiki S, Amakata Y. Thyroxine-induced production of superoxide anion by human alveolar neutrophils and macrophages: a possible mechanism for the exacerbation of bronchial asthma with the development of hyperthyroidism. In Vivo 1998, 12:253-257.
130. Foster MP, Montecino-Rodriguez E, Dorshkind K. Proliferation of bone marrow pro-B cells is dependent on stimulation by the pituitary/thyroid axis. J Immunol 1999, 163:5883-5890.
131. Huang SA, Bianco AC. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab 2008, 4:148-155.
132. Torpy DJ, Tsigos C, Lotsikas AJ, Defensor R, Chrousos GP, Papanicolaou DA. Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humans. Metabolism 1998, 47:1289-1293.
133. Kumar K, Kole AK, Karmakar PS, Ghosh A. The spectrum of thyroid disorders in systemic lupus erythematosus. Rheumatol Int 2012, 32:73-78.
134. Hashimoto H, Igarashi N, Yachie A, Miyawaki T, Hashimoto T, Sato T. The relationship between serum levels of interleukin-6 and thyroid hormone during the follow-up study in children with nonthyroidal illness: marked inverse correlation in Kawasaki and infectious disease. Endocr J 1996, 43:31-38.
135. Raterman HG, Jamnitski A, Lems WF, Voskuyl AE, Dijkmans BA, Bos WH, Simsek S, Lips P, van de Stadt RJ, de Koning MH, Nurmohamed MT. Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study. J Rheumatol 2011, 38:247-251.
136. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev 2011, 32:670-693.
137. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010, 2:247-257.
138. Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, Pazmino AK, Facemire C, Chen BJ, Kim HS, Tran TT, Pisetsky DS, Barisoni L, Prieto-Carrasquero MC, Jeansson M, Foster MH, Coffman TM. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009, 119:943-953.
139. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford) 2005, 44:24-31.
140. Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. Arthritis Rheum 2005, 52:1920-1928.
141. Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, Zhang J, Crumpacker CS. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog 2009, 5:e1000427.
142. Ohtani R, Ohashi Y, Muranaga K, Itoh N, Okamoto H. Changes in activity of the renin-angiotensin system of the rat by induction of acute inflammation. Life Sci 1989, 44:237-241.
143. Doerschug KC, Delsing AS, Schmidt GA, Ashare A. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care 2010, 14:R24.
144. Walsh DA, Catravas J, Wharton J. Angiotensin converting enzyme in human synovium: increased stromal [(125)I]351A binding in rheumatoid arthritis. Ann Rheum Dis 2000, 59:125-131.
145. Samoriadova OS, Zharova EA, Masenko VP, Balabanova RM, Vil'chinskaia MI, Nasonov EL. The renin-angiotensin-aldosterone system and arterial hypertension in patients with rheumatoid arthritis. Klin Med (Mosk) 1991, 69:69-71.
146. Shilkina NP, Stoliarova SA, Iunonin IE, Driazhenkova IV. Neurohumoral regulation of blood pressure in rheumatic patients. Ter Arkh 2009, 81:37-41.
147. Vanhorebeek I, Langouche L, Van den Berghe G. Endocrine aspects of acute and prolonged critical illness. Nat Clin Pract Endocrinol Metab 2006, 2:20-31.
148. Cutolo M, Seriolo B, Villaggio B, Pizzorni C, Craviotto C, Sulli A. Androgens and estrogens modulate the immune and inflammatory responses in rheumatoid arthritis. Ann N Y Acad Sci 2002, 966:131-142.
149. Cutolo M, Pizzorni C, Sulli A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 2011, 11:84-87.